Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jackson Alice M, Rørth Rasmus, Liu Jiankang, Kristensen Søren Lund, Anand Inder S, Claggett Brian L, Cleland John G F, Chopra Vijay K, Desai Akshay S, Ge Junbo, Gong Jianjian, Lam Carolyn S P, Lefkowitz Martin P, Maggioni Aldo P, Martinez Felipe, Packer Milton, Pfeffer Marc A, Pieske Burkert, Redfield Margaret M, Rizkala Adel R, Rouleau Jean L, Seferović Petar M, Tromp Jasper, Van Veldhuisen Dirk J, Yilmaz Mehmet B, Zannad Faiez, Zile Michael R, Køber Lars, Petrie Mark C, Jhund Pardeep S, Solomon Scott D, McMurray John J V, PARAGON-HF Committees and Investigators
Аннотация
METHODS AND RESULTS: Patients aged ≥50 years with left ventricular ejection fraction ≥45%, structural heart disease and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) were eligible. Patients were classified according to glycated haemoglobin (HbA1c): (i) normal HbA1c, <6.0%; (ii) pre-diabetes, 6.0%-6.4%; (iii) diabetes, ≥6.5% or history of diabetes. The primary outcome was a composite of cardiovascular (CV) death and total heart failure hospitalizations (HFH). Of 4796 patients, 50% had diabetes and 18% had pre-diabetes. Compared to patients with normal HbA1c, patients with pre-diabetes and diabetes more often were obese, had a history of myocardial infarction and had lower Kansas City Cardiomyopathy Questionnaire scores, while patients with diabetes had more clinical evidence of congestion, but similar NT-proBNP concentrations. The risks of the primary composite outcome (rate ratio [RR] 1.59, 95% confidence interval [CI] 1.35-1.88), total HFH (RR 1.67, 95% CI 1.39-2.02) and CV death (hazard ratio [HR] 1.35, 95% CI 1.07-1.71) were higher among patients with diabetes, compared to those with normal HbA1c. Patients with pre-diabetes had a higher risk (which was intermediate between that of patients with diabetes and those with normal HbA1c) of the primary outcome (HR 1.27, 95% CI 1.00-1.60) and HFH (HR 1.35, 95% CI 1.03-1.77), but not of CV death (HR 1.02, 95% CI 0.75-1.40). Patients with diabetes treated with insulin had worse outcomes than those not, and those with 'lean diabetes' had similar mortality rates to those with a higher body mass index, but lower rates of HFH.
CONCLUSION: Pre-diabetes is common in patients with HFpEF and is associated with worse clinical status and greater risk of HFH.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01920711.